Progyny (NASDAQ:PGNY) Director Kevin Gordon Sells 11,500 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) Director Kevin Gordon sold 11,500 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the sale, the director owned 6,792 shares in the company, valued at $189,768.48. This represents a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Progyny Stock Performance

NASDAQ:PGNY traded up $0.50 during mid-day trading on Monday, hitting $27.85. 929,921 shares of the company’s stock traded hands, compared to its average volume of 1,418,871. The firm’s 50 day simple moving average is $28.71 and its 200 day simple moving average is $24.03. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $33.06. The company has a market cap of $2.14 billion, a PE ratio of 30.27, a price-to-earnings-growth ratio of 1.89 and a beta of 0.99.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. During the same period in the prior year, the business earned $0.19 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, research analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has approved a share repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

PGNY has been the topic of several recent research reports. Bank of America upped their price objective on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, August 21st. Leerink Partners set a $38.00 target price on shares of Progyny in a report on Wednesday, July 22nd. Weiss Ratings cut shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, KeyCorp lifted their price target on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Progyny has a consensus rating of “Moderate Buy” and an average target price of $34.36.

Institutional Investors Weigh In On Progyny

Hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new position in Progyny during the second quarter worth about $29,000. Nykredit A S purchased a new stake in Progyny in the 2nd quarter valued at about $38,000. Hantz Financial Services Inc. grew its holdings in Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after buying an additional 742 shares during the period. IFP Advisors Inc increased its stake in shares of Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after acquiring an additional 1,549 shares during the last quarter. Finally, Toth Financial Advisory Corp purchased a new position in shares of Progyny during the 2nd quarter worth about $65,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.